Phase IIa data for CVAS's rNAPc2

Corvas (CVAS) said data from a double-blind, placebo-controlled European Phase IIa study showed that its rNAPc2 anticoagulant was safe, well-tolerated and suppressed thrombin formation in 156 patients...